向日葵(300111.SZ):注射用艾司奧美拉唑鈉獲藥品註冊批件
格隆匯6月8日丨向日葵(300111.SZ)公佈,公司控股子公司浙江貝得藥業有限公司近日收到國家藥品監督管理局下發的《藥品註冊批件》,藥品名稱:注射用艾司奧美拉唑鈉。
注射用艾司奧美拉唑鈉適應症:作為當口服療法不適用時,胃食管反流病的替代療法;用於口服療法不適用的急性胃或十二指腸潰瘍出血的低危患者(胃鏡下Forrest分級IIc-III)。
公司控股子公司注射用艾司奧美拉唑鈉獲得國家藥品監督管理局的《藥品註冊批件》,使公司具備了在國內市場銷售該藥品的資格,進一步豐富了公司的產品線,有助於提升公司產品的市場競爭力。
值得注意的是,公司在取得藥品註冊批件後,可生產本品並上市銷售,上述藥品的生產、銷售情況容易受內外部環境變化等多種因素的影響,存在一定的不確定性。敬請廣大投資者謹慎決策,注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.